Oscar Health, Inc. (OSCR) Down 8.2% — Should I Let It Go?
Oscar Health, Inc. (OSCR) is under heavy selling pressure this Friday, last changing hands at $30.46 on the NYSE. That is a $2.72 drop from the prior close of $33.18 and a sharp reversal for a stock that was hitting fresh highs just days ago. OSCR set its 52-week high of $36.16 on November 4, 2026, and the current quote sits roughly 15.8% below that level. Two sessions have been enough to erase a meaningful share of the run-up into earnings.
Volume has reached about 4.22 million shares so far in the session, compared with a 90-day average of roughly 5.22 million. With the regular session still open, turnover is tracking toward a normal day rather than a capitulation-style flush.
Why Oscar Health, Inc. Price is Moving Lower
The decline appears to reflect a pullback in insurers exposed to the Affordable Care Act marketplaces, along with investor doubts about how durable Oscar's earnings recovery really is. It does not reflect a weak quarter. Centene (CNC), another major ACA-focused carrier, fell 6.39% in the same session, while the S&P 500 rose 0.77% and the Health Care Select Sector SPDR (XLV) gained 0.15%. That divergence points to pressure concentrated in marketplace-heavy insurers rather than a broad risk-off move. Insurance names more generally were soft as well, with The Allstate Corporation (ALL) down 3.71% and The Progressive Corporation (PGR) off 1.47%. OSCR's 8.21% slide is far steeper than either.
The irony is that the November 5 report was strong on its face. Oscar posted Q3 diluted EPS of $0.49 against analyst expectations for a $0.14 loss. Revenue reached $5.14 billion versus the $4.69 billion consensus, a 72.1% increase from $2.99 billion a year earlier. Net income swung to $167.3 million from a $137.5 million loss, and the medical loss ratio improved to 84.0% from 88.5%. Management also raised its 2026 operating-earnings guidance to a range of $850 million to $950 million, up from $600 million to $800 million.
The market's scrutiny has turned to the quality and sustainability of those numbers. Q3 revenue included a $250 million benefit from updated risk-adjustment estimates, which flatters the headline results and is not the kind of item investors can extrapolate. Looking ahead, management said its planned 2027 average premium increase is about 14%, while underlying medical-cost trend is running in the high single digits. That leaves investors to judge whether pricing can stay ahead of costs. Piper Sandler trimmed its price target to $45 from $48 on November 6 but kept its Overweight rating, and that target still sits well above where the stock is trading. Coming off a fresh 52-week high, the reassessment has produced a sharp give-back.
What is the Oscar Health, Inc. Rating - Should I Sell?
Weiss Ratings assigns OSCR a B- rating. Current recommendation is Buy. The B- reflects a company whose operating turnaround and balance sheet have improved substantially. That strength is partly offset by a share price that can swing hard on shifts in sentiment toward the ACA marketplace, as this week has shown.
The strongest parts of the profile are Oscar's financial footing and what it has delivered to shareholders. The Excellent rating on the Solvency Index suggests the balance sheet can absorb the reserve and pricing uncertainty that comes with marketplace exposure, which matters for an insurer facing elevated medical-cost trend heading into 2027. The Total Return Index is also rated Excellent. Even after today's decline, the stock remains within about 16% of a 52-week high set only two days earlier, so holders over the measurement period have been well rewarded. Growth is rated Good, supported by 70.40% revenue growth, an exceptional pace for a company already generating more than $5 billion in quarterly revenue. The rating stops short of Excellent, a reasonable call given that the latest quarter leaned on a $250 million risk-adjustment benefit.
Where the picture becomes more nuanced is profitability and price stability. The Good rating on the Efficiency Index draws support from a 34.26% ROE, a strong return for an insurer that was posting losses a year ago. A 3.59% profit margin shows how little of each premium dollar Oscar keeps once medical claims are paid, so small changes in cost trend can swing results sharply. The Weak Volatility Index is the clearest drag on the overall rating. An 8.21% single-session drop driven by sector-wide doubts about ACA insurers, in a week when the stock also set a new high, illustrates why the Volatility Index is not rated higher. A forward P/E of 25.38 also leaves limited room for disappointment if 2027 pricing fails to keep pace with costs.
Within the Financials sector, Oscar Health is on par with The Progressive Corporation (PGR, B-) and slightly behind MetLife, Inc. (MET, B). It trails The Travelers Companies, Inc. (TRV, A+), The Allstate Corporation (ALL, A+), and Manulife Financial Corporation (MFC, A+), all of which combine strong fundamentals with steadier price behavior.
About Oscar Health, Inc.
Oscar Health, Inc. (OSCR) is a Financials company operating in the Insurance industry. It runs a technology-driven health insurance business headquartered in New York. Founded in 2012, Oscar built its model around the individual market created by the Affordable Care Act. It offers individual and family health plans on state and federal exchanges across a broad multistate footprint, and that marketplace business remains the core of its revenue and the main source of its exposure to federal policy and risk-adjustment mechanics.
Oscar distinguishes itself through a member experience built on its own technology stack rather than legacy insurance systems. Members use the Oscar app to find in-network providers, manage claims, and reach virtual care. Care-routing tools and dedicated concierge teams steer members toward cost-effective treatment. The company has also leaned into individual coverage health reimbursement arrangements (ICHRA), which let employers fund workers' purchases of individual-market plans and create a potential channel for growth beyond traditional exchange enrollment. Through +Oscar, the company extends its platform capabilities to outside providers and payers.
Oscar's competitive edge rests on its proprietary platform, its data-driven approach to network design and medical management, and a brand that resonates with consumers who shop for coverage directly. These advantages help it compete against much larger managed-care incumbents in the marketplace segment. However, the business remains closely tied to the regulatory structure, subsidy levels, and risk-adjustment framework governing the ACA exchanges.
Investor Outlook
Oscar Health, Inc. (OSCR) carries a Weiss Rating of B- (Buy), backed by a sharply improved earnings profile and a strong balance sheet, though recent price swings argue for measured position sizing. Investors should watch whether the planned 14% average premium increase for 2027 holds up against high-single-digit medical-cost trend, and whether earnings stay strong once one-time risk-adjustment benefits fade. See full rankings of all B- rated Financials stocks inside the Weiss Stock Screener.
--